Simbiosys

Enabling Precision Surgery: Ricoh 3D for Healthcare and SimBioSys to Explore Collaboration for Development of AI-Powered Personalized 3D-Printed Models

Retrieved on: 
Thursday, April 11, 2024
Research, Technology, Medical Devices, Surgery, Other Health, Biotechnology, Health, Science, Oncology, Artificial Intelligence, FDA, Ricoh, AI, Health care, Surgeon, Artificial intelligence, 3D, Simbiosys, Patient, Society, Breast cancer

(“SimBioSys”) today announced a collaborative initiative to explore cutting-edge technologies with the potential to aid the treatment of breast cancer.

Key Points: 
  • (“SimBioSys”) today announced a collaborative initiative to explore cutting-edge technologies with the potential to aid the treatment of breast cancer.
  • SimBioSys, known for its revolutionary TumorSightTM technology, the first digital precision medicine platform, and Ricoh, via its Ricoh 3D for Healthcare business (“Ricoh 3D for Healthcare”), a leader in the manufacturing of patient-specific medical devices, are set to showcase the potential of their combined technologies.
  • Ricoh 3D for Healthcare and SimBioSys will unveil some of their first AI-generated, 3D-printed breast cancer models at the upcoming American Society of Breast Surgeons (“ASBrS”) conference.
  • The integrated SimBioSys and Ricoh 3D for Healthcare workflow is currently for educational purposes only and not FDA cleared (or otherwise cleared) for diagnostic use or other uses.

SimBioSys Launches TumorSight Plan, A Pioneering Clinical Decision Support for Early-Stage Breast Cancer

Retrieved on: 
Tuesday, April 9, 2024
Technology, Biotechnology, Health, Consumer, Other Health, Radiology, Surgery, Artificial Intelligence, Oncology, Medical Devices, Software, General Health, Health Technology, Women, Breast cancer, MRI, Breast Cancer Care, Mastectomy, Science, Patient, Artificial intelligence, 3D, Cancer, Surgeon, Woman, Risk assessment, CMO, Simbiosys, FDA, Medicine, Medical imaging

Now, with TumorSight Plan, surgeons are empowered with visualization, data-driven insights, and best-practices to help support more effective provider-patient interactions and individualize treatment planning to right-size care.

Key Points: 
  • Now, with TumorSight Plan, surgeons are empowered with visualization, data-driven insights, and best-practices to help support more effective provider-patient interactions and individualize treatment planning to right-size care.
  • TumorSight Plan is powered by the FDA-cleared TumorSight Viz , an innovative 3D visualization solution to support the rapidly increasing use of MRI imaging in Breast Cancer.
  • SimBioSys’ TumorSight suite is a huge breakthrough in our capacity to utilize AI to calibrate a balance between decision standardization and individualized medicine.
  • TumorSight Plan gives the breast cancer surgeon a platform and opportunity to enable more analytical patient-centric decision making which should lead to higher percentage of women undergoing breast conservation surgery.”

Precision Oncology Innovator SimBioSys and General Inception Announce Strategic Partnership to Accelerate Cancer Drug Development

Retrieved on: 
Wednesday, April 3, 2024
Pyrotechnic initiator, Partnership, Patient, Neoplasm, Biomarker, Credentialing, Cancer, AI, Drug development, PALO, Clinical trial, Therapy, Simbiosys, Pharmaceutical industry

CHICAGO & PALO ALTO, Calif., April 3, 2024 /PRNewswire/ -- SimBioSys, a leading innovator in precision oncology, and General Inception ("GI"), a global company Igniter, today announce a strategic partnership that aims to significantly reduce oncology drug development times and cut development costs by using AI and biophysical modeling to better understand unique tumor spatial biophysical characteristics.

Key Points: 
  • Drug development in oncology is at high levels, with more than 2,000 products currently under development and drug trial starts up 22% in 2022 from 2018.
  • [1]
    Venkat Reddy, Chief Scientific Officer of General Inception, said: "This collaboration marks a significant milestone in the pursuit of more effective, personalized cancer therapies, as all new oncology drug incubations under General Inception will be able to use SimBioSys' state-of-the-art PhenoScope platform and drug development services.
  • Tushar Pandey, Chief Executive Officer of SimBioSys, said: "Together, we are committed to introducing much-needed precision to the drug development process.
  • By partnering with General Inception, we can cut their oncology drug development time and costs significantly.

Precision Oncology Innovator SimBioSys and General Inception Announce Strategic Partnership to Accelerate Cancer Drug Development

Retrieved on: 
Wednesday, April 3, 2024
Pyrotechnic initiator, Partnership, Patient, Neoplasm, Biomarker, Credentialing, Cancer, AI, Drug development, PALO, Clinical trial, Therapy, Simbiosys, Pharmaceutical industry

CHICAGO & PALO ALTO, Calif., April 3, 2024 /PRNewswire/ -- SimBioSys, a leading innovator in precision oncology, and General Inception ("GI"), a global company Igniter, today announce a strategic partnership that aims to significantly reduce oncology drug development times and cut development costs by using AI and biophysical modeling to better understand unique tumor spatial biophysical characteristics.

Key Points: 
  • Drug development in oncology is at high levels, with more than 2,000 products currently under development and drug trial starts up 22% in 2022 from 2018.
  • [1]
    Venkat Reddy, Chief Scientific Officer of General Inception, said: "This collaboration marks a significant milestone in the pursuit of more effective, personalized cancer therapies, as all new oncology drug incubations under General Inception will be able to use SimBioSys' state-of-the-art PhenoScope platform and drug development services.
  • Tushar Pandey, Chief Executive Officer of SimBioSys, said: "Together, we are committed to introducing much-needed precision to the drug development process.
  • By partnering with General Inception, we can cut their oncology drug development time and costs significantly.

SimBioSys® Elevates Leadership Team as It Receives First FDA Clearance for Digital Precision Medicine Platform, TumorSight™

Retrieved on: 
Friday, January 5, 2024
Data Management, Other Science, FDA, Technology, Research, General Health, Data Analytics, Other Health, Apps, Applications, Surgery, Pharmaceutical, Oncology, Medical Devices, Health Technology, Professional Services, Biotechnology, Artificial Intelligence, Software, Health, Science, Medicine, Jyoti, CCO, McKinsey & Company, Cancer, Artificial intelligence, Simbiosys, Growth, Patient, Alió, Management

The announcement coincides with the company's landmark achievement of receiving FDA clearance for its groundbreaking TumorSight™ platform.

Key Points: 
  • The announcement coincides with the company's landmark achievement of receiving FDA clearance for its groundbreaking TumorSight™ platform.
  • A distinguished HealthTech executive, Palaniappan brings a wealth of experience from notable roles at Abbott, Thermo Fisher Scientific, and McKinsey.
  • Tushar Pandey, Chief Executive Officer of SimBioSys, expressed enthusiasm about Palaniappan's appointment, stating, “We are thrilled to welcome Jyoti to the SimBioSys team.
  • The recent FDA clearance is just the beginning, and I look forward to collaborating with Tushar and the SimBioSys team to accelerate our strategy and boldly advance the future of precision medicine in oncology to deliver better outcomes for patients.”

SimBioSys and UT Southwestern Enter Strategic Collaboration to Advance Multi-Modal Data Analysis and the Next Generation of Cancer Biomarkers for Immunotherapy

Retrieved on: 
Monday, December 18, 2023
Technology, Biotechnology, Health, Radiology, Surgery, Professional Services, Artificial Intelligence, Oncology, Research, Hospitals, Data Analytics, Science, Data Management, Clinical Trials, Toxicity, Breast cancer, Genomics, Patient, Tumor microenvironment, Artificial intelligence, Internal medicine, Molecular biology, Drug discovery, Cancer, Medical imaging, Simbiosys

As part of this collaboration, the Chan Lab at UT Southwestern will enhance PhenoScope’s tumor bank with valuable spatial transcriptomic data and provide advanced bioinformatic analytic expertise.

Key Points: 
  • As part of this collaboration, the Chan Lab at UT Southwestern will enhance PhenoScope’s tumor bank with valuable spatial transcriptomic data and provide advanced bioinformatic analytic expertise.
  • Dr. Isaac Chan, an Assistant Professor in UT Southwestern’s Departments of Internal Medicine and Molecular Biology, will be the primary advisor for the collaboration.
  • “We are honored to be collaborating with UT Southwestern, a leading cancer research institution, and Dr. Chan,” said Tushar Pandey, co-founder and CEO of SimBioSys.
  • The presentation is titled, “Genomics and Personalized Medicine - how genomics is impacting personalized medicine and its future role within cancer drug discovery.”

SimBioSys Presents New Data for Breast Cancer Personalized Medicine Platforms at the 46th Annual San Antonio Breast Cancer Symposium

Retrieved on: 
Tuesday, December 12, 2023
Biotechnology, Health, Biometrics, Surgery, Oncology, Other Science, Research, General Health, Hospitals, Genetics, Health Technology, Health Insurance, Science, Clinical Trials, Forecast, Neoplasm, Neoadjuvant therapy, Breast cancer, Surgeon, Perfusion, Patient, Tumor microenvironment, NAT, Artificial intelligence, BCS, Gene expression, Radiomics, Mastectomy, HER2, Cancer, PET, SOC, DCE, Medical imaging, Medical device, Dentistry, Health insurance, Simbiosys

SimBioSys, a TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and data science to redefine precision medicine for cancer with software tools, recently presented new data from its TumorSight and PhenoScope platforms at the 46th Annual San Antonio Breast Cancer Symposium (SABCS), held from December 5-9, 2023.

Key Points: 
  • SimBioSys, a TechBio company unlocking the power of spatial biophysics with artificial intelligence (AI) and data science to redefine precision medicine for cancer with software tools, recently presented new data from its TumorSight and PhenoScope platforms at the 46th Annual San Antonio Breast Cancer Symposium (SABCS), held from December 5-9, 2023.
  • The results included collaborations with top cancer research institutions, multi-institutional analysis, enhanced visualization, and volumetric prediction capabilities to aid surgical planning.
  • (PO2-02-11) Radiomics and an Erosion Model to Predict Post-Neoadjuvant Therapy Tumor Characteristics for Personalized Breast Cancer Treatment.
  • Research Summary: Early breast cancer Patient Opinion Leaders (POLs) and surgeons were surveyed to assess TumorSight’s potential impact on shared decision making for breast cancer surgical options.

Providing the best "patient-centered" care in breast cancer - how new technology could help us realize the meaning of truly "personalized medicine"

Retrieved on: 
Monday, October 30, 2023
3D, Anatomy, FDA, Neoplasm, MRI, Patient, Radiology, Thought, Life, Breast Cancer Awareness Month, Fear, Disease, Medicine, Surgeon, Biology, Silver, Breast cancer, IQ, Hospital, Simbiosys, ASAP, Woman, Oncology, Cancer, AI, Mastectomy, Breast, Diagnosis, Dentistry, Birth control, Nursing, Medical imaging, Symbiosis

CHICAGO, Oct. 30, 2023 /PRNewswire-PRWeb/ -- As Breast Cancer Awareness Month comes to a close, we continue to celebrate survivors, mourn those we've lost, and reflect on how we can better serve our patients so that they may live longer and live better.

Key Points: 
  • New advancements in technology, including SimBioSys' TumorSight™ Plan, have the potential to revolutionize patient-centered care and personalized medicine in breast cancer.
  • Dr. Barry Rosen, an oncoplastic breast surgeon and educator, discusses the challenges in breast cancer surgery and how these new tools can potentially help doctors and patients alike.
  • Dr. Rosen notes that while this is a nice sentiment, the actual care provided does not often fit what is practiced in medicine.
  • "From a historical perspective, until the 1980's the only real treatment option for breast cancer was removal of the entire breast, a mastectomy.

SimBioSys Partners with CancerX to Accelerate Innovation in Cancer Care

Retrieved on: 
Wednesday, August 23, 2023
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Artificial Intelligence, Health Technology, Technology, Partnership, Life, HHS, Simbiosys, Health equity, Cancer, MBA, Surgeon, Patient, Medicine, Artificial intelligence, FACS, AI, H. Lee Moffitt Cancer Center & Research Institute, MPH, Dime, Organization, Pharmaceutical industry

Announced by the White House Cancer Moonshot, CancerX is a public-private partnership to boost innovation in the fight against cancer co-hosted by the Digital Medicine Society (DiMe) and Moffitt Cancer Center.

Key Points: 
  • Announced by the White House Cancer Moonshot, CancerX is a public-private partnership to boost innovation in the fight against cancer co-hosted by the Digital Medicine Society (DiMe) and Moffitt Cancer Center.
  • CancerX uniquely blends DiMe's expertise in convening cross-disciplinary groups to develop clinical-quality resources on a tech timeline with Moffitt's top research and care experts working side-by-side to revolutionize cancer treatment, extend access to the highest-quality care, and save more lives.
  • “Multi-stakeholder collaboration is critical to harness the potential of digital innovation in the fight against cancer, and we're honored to partner with SimBioSys to achieve the ambitious goals of CancerX," said Smit Patel, associate program director at DiMe.
  • By supporting startups in scaling their operations and emphasizing health equity, CancerX aims to announce their first demonstration project in April 2024.

SimBioSys® highlights key advances for medical and surgical planning in breast cancer at SABCS 2022

Retrieved on: 
Tuesday, December 6, 2022
Science, Biotechnology, Research, Surgery, Oncology, General Health, Health, Health Technology, University of North Carolina, Chain reaction, University of Cincinnati, University of Chicago, Research, Biomarker, Patient, Cancer, Breast cancer, Disease, Artificial intelligence, UNC Lineberger Comprehensive Cancer Center, University, Medical imaging, Pharmaceutical industry, Simbiosys

SimBioSys, the precision oncology company behind the 4D Tumor Modelingtechnology, is presenting their latest breast cancer research and introducing new technology applications at the 2022 San Antonio Breast Cancer Symposium (SABCS).

Key Points: 
  • SimBioSys, the precision oncology company behind the 4D Tumor Modelingtechnology, is presenting their latest breast cancer research and introducing new technology applications at the 2022 San Antonio Breast Cancer Symposium (SABCS).
  • The studies covering six separate poster presentations at SABCS are based on data from both internal and external validation studies of SimBioSys proprietary platform.
  • The results include collaborations with top cancer research institutions, multi-institutional analysis, enhanced visualization, and volumetric prediction capabilities to aid surgical planning as well as novel biomarkers.
  • We are incredibly proud of the research and clinical collaborations with key leaders in breast cancer and the impact our technology can have in breast cancer care, said Dr. Anuja Antony, Chief Medical Officer of SimBioSys.